RBC Capital Initiates Coverage On Attovia Therapeutics with Outperform Rating, Announces Price Target of $45

Benzinga Newsdesk www.benzinga.com Positive 60.4%

Neg 0% Neu 0% Pos 60.4%

RBC Capital analyst Brian Abrahams initiates coverage on Attovia Therapeutics (NASDAQ:ATTO) with a Outperform rating and announces Price Target of $45.